Graduated in Pharmacy from the Federal University of Ceará (2003), qualification in Industrial Pharmacy from the Federal University of Ceará (2005), Master's in Pharmacology from the Federal University of Ceará (2005) and Ph.D. in Pharmacology from the Federal University of Ceará (2008), and held a postdoctoral degree at Weill Cornell Medical College (New York, NY, United States) (2019/2020). He is a researcher at the Oswaldo Cruz Foundation-Fiocruz-Bahia and permanent professor in the postgraduate program in Biotechnology in Health and Investigative Medicine at Fiocruz-Bahia (Capes 6 concept) and in the postgraduate program in Pharmacy at UFBA (Capes concept 4). Member of the National Institute of Science and Technology INCT - North and Northeast Network of Phytoproducts (RENNOFITO), American Association for Cancer Research (AACR) and Brazilian Society of Pharmacology and Experimental Therapeutics (SBFTE). He works in the preclinical development of new anticancer drugs. Currently mainly involved in the study of: ruthenium complexes; natural products; oxidative stress; cell signaling pathways including MAPK, NF-#954;B, PI3K/AKT/mTOR and p53; apoptosis, autophagy, hepatocellular carcinoma; colon carcinoma; acute myeloid leukemia; and cancerous/leukemic stem cells.
Possui graduação em Farmácia (modalidade indústria) pela Universidade Federal do Ceará, mestrado e doutorado em Farmacologia pela Universidade Federal do Ceará, e realizou pós-doutorado na Weill Cornell Medical College (Nova York, NY, Estados Unidos). Foi pesquisador visitante na The University of Texas MD Anderson Cancer Center (Houston, Texas, Estados Unidos) com bolsa do programa Fulbright. É pesquisador da Fundação Oswaldo Cruz - Fiocruz - Bahia e professor permanente do programa de pós-graduação em Biotecnologia em Saúde e Medicina Investigativa da Fiocruz - Bahia (conceito Capes 6). Membro do Instituto Nacional de Ciência Tecnologia INCT - Rede Norte e Nordeste de Fitoprodutos (RENNOFITO), American Association for Cancer Research (AACR) e Sociedade Brasileira de Farmacologia e Terapêutica Experimental (SBFTE). Membro do AACR Maximizing Opportunity for New Advancements in Research in Cancer (MONARCA) Grants for Latin America Scientific Review Committee (2022-2024). Atua no desenvolvimento pré-clínico de novos medicamentos antineoplásicos. Atualmente envolvido principalmente no estudo de: complexos de rutênio; produtos naturais; estresse oxidativo; vias de sinalização celular, incluindo MAPK, NF-#954;B, PI3K/AKT/mTOR e p53; apoptose, autofagia, carcinoma hepatocelular; carcinoma do cólon; leucemia mielóide aguda; e células-tronco cancerosas/leucêmicas.
